Tag: been-counting
-
Lilly’s drug for Alzheimer’s fails big trial; shares drop
The failure of Eli Lilly and Co’s Alzheimer’s treatment to slow declines in mental capacity of patients with even mild symptoms cast serious doubt over whether a long-held approach to the memory-robbing disease could provide meaningful benefit to millions of people at risk. Many investors and families had been counting on solanezumab to become the…
-
Roche confident in Alzheimer’s program, despite Lilly flop
Roche said on Wednesday it still believed drugs targeting a protein called beta amyloid had potential to help fight Alzheimer’s disease, despite the high-profile failure of such a product from Eli Lilly. As the setback sent shares in Lilly skidding, Roche pointed out there were significant differences between two experimental Alzheimer’s drugs it was developing…